<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975234</url>
  </required_header>
  <id_info>
    <org_study_id>Mio/Reg/Quirur/Aleatorizado</org_study_id>
    <nct_id>NCT00975234</nct_id>
  </id_info>
  <brief_title>Treatment With Autologous Skeletal Myoblasts</brief_title>
  <official_title>Phase II, Randomised, Controlled Study of Treatment With Revascularisation Surgery With or Without Injection of Autologous Skeletal Myoblasts in Patients With Old Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fina Biotech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the benefit of autologous skeletal myoblast
      injection in patients with old myocardial infarction and ventricular dysfunction versus
      conventional revascularisation therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischaemic heart disease is one of the main causes of mortality and morbidity. In particular,
      myocardial infarction (MI) is of special significance, as the heart muscle cannot regenerate
      so a region's necrosis leads to the formation of a fibrous scar. Depending on the area
      affected by the scar, infarction can lead to a progressive and irreversible decline in
      cardiac function, giving way to heart failure (HF) syndrome. The molecular basis of
      congestive heart failure is the absence of cardiac stem cells capable of regenerating cardiac
      muscle. In the skeletal muscle, there are cells located beneath the basal membrane with are
      capable of regenerating muscle fibres; they are known as myoblasts. There are several studies
      with autologous myoblasts, either by direct administration during surgery or percutaneously,
      which could distinguish between the effect of revascularisation surgery and that of the
      myoblast injection. The objective of this study is compare improvement in global and regional
      cardiac function in patients with old MI obtained by aortocoronary bypass surgery with
      intracardiac administration of autologous skeletal myoblasts versus standard aortocoronary
      bypass surgery treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoints will be evaluate the ejection fraction and wall motion score index measured by M-mode and echocardiography 12 months after surgery.</measure>
    <time_frame>12 months after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy endpoints are viability, perfusion and thickening and incidence of cardiac arrhythmias.</measure>
    <time_frame>12 month after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Old Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Skeletal myoblasts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are receiving skeletal myoblasts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Revascularisation surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intra-lesion injection of autologous skeletal myoblasts</intervention_name>
    <description>Intra-lesion injection</description>
    <arm_group_label>Skeletal myoblasts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Revascularisation</intervention_name>
    <description>Revascularisation surgery</description>
    <arm_group_label>Skeletal myoblasts</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of coronary disease obtained by coronary angiography who
             require conventional aortocoronary bypass surgery.

          -  History of myocardial infarction with evidence of regional akinesis (or dyskinesia)
             for more than 4 weeks and less than 10 years.

          -  Ejection fraction from 25% to 45%.

          -  Evidence of no regional viability by dobutamine echocardiography.

          -  Aged from 30-80 years old.

          -  Negative serology to HIV, HBV and HCV.

          -  Patients without organ dysfunction.

          -  Negative pregnancy test (women of childbearing age).

          -  Informed consent granted.

        Exclusion Criteria:

          -  History of myocardial infarction in the 4 weeks prior to the inclusion in the study.

          -  Prior history of tachycardia or ventricular fibrillation (except in patients with DAI
             device).

          -  History of cancer (except basocellular carcinoma) or prior treatment with
             chemotherapy.

          -  The patient should not suffer from any concomitant severe and/or uncontrolled medical
             condition.

          -  Patients who, due to their geographical, psychiatric or social status, have
             difficulties in meeting the conditions established in the protocol.

          -  Pregnant or beast feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Prósper, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinica Universidad de Navarra</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intra-lesion injection of autologous myoblasts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

